These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38341323)

  • 1. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
    Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
    J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
    Agarwala A; Quispe R; Goldberg AC; Michos ED
    Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Goldberg AC; Banach M; Catapano AL; Duell PB; Leiter LA; Hanselman JC; Lei L; Mancini GBJ
    Atherosclerosis; 2023 Nov; 384():117192. PubMed ID: 37648637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
    Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
    J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS; Sulaica EM; Beavers CJ
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).
    Ballantyne CM; Banach M; Bays HE; Catapano AL; Laufs U; Stroes ESG; Robinson P; Lei L; Ray KK
    Am J Cardiol; 2022 Jul; 174():1-11. PubMed ID: 35483979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bempedoic Acid: A New Drug for an Old Problem.
    Nguyen D; Du N; Sulaica EM; Wanat MA
    Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
    Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
    J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
    Ginsberg HN; Tuomilehto J; Hovingh GK; Cariou B; Santos RD; Brown AS; Sanganalmath SK; Koren A; Thompson D; Raal FJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):69-76. PubMed ID: 30734207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Shapiro MD; Taub PR; Louie MJ; Lei L; Ballantyne CM
    Atherosclerosis; 2023 Aug; 378():117182. PubMed ID: 37517922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.